首页> 外文会议>International Conference on Software Engineering Research, Management and Applications >Investigating the Capability of Agile Processes to Support Life-Science Regulations: The Case of XP and FDA Regulations with a Focus on Human Factor Requirements
【24h】

Investigating the Capability of Agile Processes to Support Life-Science Regulations: The Case of XP and FDA Regulations with a Focus on Human Factor Requirements

机译:调查敏捷过程的能力,以支持生命 - 科学规定:XP和FDA规定的案例,重点是人为因素要求

获取原文

摘要

Recently, there has been a noticeable increase of attention to regulatory compliance. As a result, more and more organizations are required to comply with the laws and regulations that apply to their industry sector. An important aspect of these regulations is directly related to the way by which software systems, used by regulated companies, are built, tested, and maintained. While some of these regulations require from these systems to support a very specific set of requirements, others, the focus of this paper, are concerned with the process by which the system has been built. The Food and Drug Administration (FDA) regulations, for example, impose stringent requirements on the process by which software systems used in medical devices are developed. One particular focus of the FDA regulations is on having a user-centered approach for building software for medical devices through the use of well-known concepts in the area of human factor engineering. In this paper, we discuss these requirements in detail and show how Extreme Programming, an agile process, lacks the necessary practices to support them. We also propose an extension to XP, that if adopted, we believe it will address this particular need of the FDA regulations for medical device software.
机译:最近,对监管合规有一个明显的关注。因此,越来越多的组织需要遵守适用于其行业部门的法律法规。这些法规的一个重要方面与受监管公司使用的软件系统建造,测试和维护的方式直接相关。虽然这些系统中的一些规定需要支持非常具体的要求,但其他系统,本文的重点涉及系统所建立的过程。例如,食品和药物管理局(FDA)法规对医疗设备中使用的软件系统产生严格的要求。 FDA法规的一个特殊重点是通过在人类因子工程领域的众所周知的概念中使用众所周知的概念来拥有用户中心用于医疗器械软件的方法。在本文中,我们详细讨论了这些要求,并展示了极端编程,敏捷过程缺乏必要的做法来支持它们。我们还提出了XP的延伸,即如果通过,我们认为它将解决这一特别需要医疗器械软件的FDA规则。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号